Australia's most trusted
source of pharma news
Thursday, 30 July 2026
Posted 30 July 2026 PM
Thirteen pharmas landed in Fortune Magazine's Fortune 500 list of US companies ranked by 2025 revenue, which revealed a sizeable win for one pharma.
Eli Lilly's success saw it jump from the pharma with the sixth largest revenue in 2024 to the second largest in 2025, after its earnings went from $45 billion to $65.2 billion. It has forecast earnings in 2026 of more than $80 billion.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.